The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
Welcome to the Newsweek Quiz - where we'll be testing your knowledge from the last seven days of news here in Wales.
A 9pm watershed ban on adverts that market junk food to children should be introduced, Wales' Health Minister has said.
It'll be an unsettled afternoon across Wales, with blustery winds and heavy rain. Gales expected in many areas.